Osteogenic PTHs and vascular ossification - Is there a danger for osteoporotics?

Journal of Cellular Biochemistry

Volumn 95, Issue 3, 2005, Pages 437-444

  Whitfield, James F ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Atheroma; Atherosclerosis; Bisphosphonates; Cholesterolemia; CVCs (calcifying vascular cells); LDL particles; Macrophages; MCP 1 chemokine; Monocytes; Osteoblasts; Osteoporosis; Pericytes; PTH (parathyroid hormone); PTHrP (parathyroid hormone related protein)

Indexed keywords

LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RECEPTOR 2; PARATHYROID HORMONE[1-34]; RETINOBLASTOMA PROTEIN; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL MODEL; ATHEROMA; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; DIABETES MELLITUS; FIBROBLAST; HEART VALVE; HUMAN; INFLAMMATION; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REVIEW; VASCULAR SMOOTH MUSCLE; ANIMAL; ARTERY; CALCINOSIS; CHEMICALLY INDUCED DISORDER; FEMALE; HEART VENTRICLE; METABOLISM; PATHOLOGY; POSTMENOPAUSE OSTEOPOROSIS; VASCULAR DISEASE;

ANIMALS; ARTERIES; CALCINOSIS; FEMALE; HEART VENTRICLES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE-RELATED PROTEIN; VASCULAR DISEASES;

EID: 23944522401     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20424     Document Type: Review

References (60)

1. Abedin M, Tintut Y, Demer LL. 2004. Vascular calcification. Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24:1161-1170.
2. Aubin JE, Triffitt JER. 2002. Mesenchymal stem cells and osteoblast differentiation. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone biology, 2nd edn. Vol. 1. San Diego, California: Academic Press. pp 59-91.
3. Barbier J-R, Neugebauer W, Morley P, Ross V, Soska M, Whitfield JF, Willick G. 1997. Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: Cyclic lactams of the receptor binding region. J Med Chem 40:1373-1380.
4. Boström KI. 2000. Cell differentiation in vascular calcification. Z Kardiol 89(Suppl 2):69-74.
5. Boström K, Demer LL. 2000. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryotic Gene Expression 12:151-158.
6. Boström K, Watson KE, Horn S, Wortham C, Herman M, Demer LL. 1993. Bone morphogenic protein expression in human atherosclerotic lesions. J Clin Invest 91:1800-1809.
7. Charo IF, Taubman MB. 2004. Chemokines in the pathogenesis of vascular disease. Circ Res 95:858-866.
8. Chen NX, Moe SM. 2003. Arterial calcification in diabetes. Curr Diab Rep 3:28-32.
9. Datta NS, Chen C, Berry JE, McCauley LK. 2004. PTHrP control of the cell cycle machinery in differentiating osteoblasts. J Bone Miner Res 19:8398.
10. De Miguel F, Fiaschi-Taesch N, López-Talavera JC, Takane KK, Massfelder T, Helwig J-J, Stewart AF. 2001. The C-terminal region of PTHrP, in addition to the nuclear localization signal, is essential for the intracrine stimulation of proliferation in vascular smooth muscle cells. Endocrinology 142:4096-4105.
11. Demer LL. 2002. Vascular calcification and osteoporosis: Inflammatory responses to oxidized lipids. Int J Epidemiol 31:737-741.
12. Demer LL, Tintut Y. 2003. Mineral exploration: Search for the mechanism of vascular calcification and beyond. Arterioscler Thromb Vasc Biol 23:1739-1743.
13. Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Aostra K, Rajavashisth TB. 2002. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 16:577-582.
14. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC, Dunstan CR, Shah PK, Rajavashisth TB. 2003a. Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 100:11201-11206.
15. Doherty TM, Shah PK, Rajavashisth TB. 2003b. Cellular origins of atherosclerosis: Towards ontogenetic end-game? FASEB J 17:592-597.
16. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK, Rajavashisth TB. 2004. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 25:629-672.
17. Engelse MA, Neele JM, Bronkers ALJJ, Pannekoek H, De Vrie CJM. 2001. Vascular calcification; expression patterns of the osteoblast-specific gene core binding factor α-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovascular Res 52:281-289.
18. Fiaschi-Taesch N, Takane KK, Masters S, Lopez-Talavera JC, Stewart AP. 2004. Parathyroid hormone-related protein as a regulator of pRB and the cell cycle of arterial smooth muscle. Circulation 110:177-185.
19. Fitzpatrick LA, Turner RT, Ritman ER. 2003. Endochondral bone formation in the heart: A possible mechanism of coronary calcification. Endocrinology 144:2214-2219.
20. Glass CK, Witztum JL. 2001. Atherosclerosis: The road ahead. Cell 104:503-516.
21. Groeneveld EHJ, Burger EH. 2000. Bone morphogenic proteins in human bone regeneration. Eur J Endocrinol 142:9-21.
22. Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H. 2004. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241-247.
23. Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Gorden M, Khalapyan T, Wolfe M, Neschis D, Milner R, Scott B, Cusack A, Mohler ER. 2002. Bone formation in carotid plaques. Stroke 33:1214-1219.
24. Iba K, Takada J, Yamashita T. 2004. The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Res 22:594-596.
25. Ishikawa M, Akishita M, Kozaki K, Toba K, Namiki A, Yamaguchi T, Orimo H, Ouchi Y. 2000. Expression of parathyroid hormone-related protein in human and experimental atherosclerotic lesions: Functional role in arterial intimal thickening. Atherosclerosis 152:97-105.
26. Jakoby MG, Semenkovich CF. 2000. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens 9:11-15.
27. Jono S, Nishizawa Y, Shioi A, Morii H. 1997. Parathyroid homone-related peptide as a local regulator of vascular calcification. Arterioscler Thromb Vasc Biol 17:1135-1142.
28. Karperien SK, Farih-Sips H, Papapoulos SE, Lowik C. 2000. Involvement of Cbfa1 in transcriptional regulation of the type 1 PTH/PTHrP receptor in KS483 osteoblasts. J Bone Miner Res 15:8175.
29. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-874.
30. Martin-Ventura JL, Ortego M, Esbrit P, Hernández-Presa MA, Ortega L, Egido J. 2003. Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis. Stroke 34:1783-1789.
31. Massfelder T, Helwig J-J. 2003. The parathyroid hormone-related protein system: More data but more unsolved questions. Curr Opin Nephrol Hypertens 12:35-42.
32. Massfelder T, Dann P, Wu TL, Vasavada R, Helwig J-J, Stewart AF. 1997. Opposing mitogenic and and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: A critical role for nuclear targeting. Proc Natl Acad Sci USA 94:13630-13635.
33. Massfelder T, Fiaschi-Taesch N, Stewart AF, Helwig J-J. 1998. Parathyroid hormone-related pepetide - A smooth muscle tone and proliferation regulatory protein. Curr Opin Nephrol Hypertens 7:27-32.
34. Nakayama T, Ohtsuru A, Enomoto H, Namba H, Ozeki S, Shibata Y, Yokota T, Nobuyoshi M, Ito M, Sekine I, Yamashita S. 1994. Coronary atherosclerotic smooth muscle cells over-express human parathyroid hormone-related peptides. Biochem Biophys Res Commun 200: 1028-1035.
35. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. 2004. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680-688.
36. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. 2002. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 15:426-444.
37. Ozeki S, Ohtsuru A, Seto S, Takeshita S, Yano H, Nakayama T, Ko M, Ykota T, Nobuyoshi M, Segre GV, Yamashita S, Yano K. 1996. Evidence that implicates the parathyroid hormonerelated peptide in vascular stenosis. Increased gene expression in the intima of injured carotid arteries and human restenoic coronary lesions. Arterioscler Thromb Vasc Biol 16:565-575.
38. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, Demer LL. 1997. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 17:680-687.
39. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. 2000. Apoptosis regulates vascular calcification in vitro. Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87:1055-1062.
40. Qiao JH, Mertens RB, Fishbein MC, Geller SA. 2003. Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: Morphologic evidence of endochondral ossification. Hum Pathol 34:402-407.
41. Rajamannan N, Subramaniam M, Rickard D, Stock S, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. 2003. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107:2181-2184.
42. Reape TJ, Groot PHE. 1999. Chemokines and atherosclerosis. Atherosclerosis 147:213-225.
43. Rubin MR, Silverberg SJ. 2004. Vascular calcification and osteoporosis. J Clin Endocrinol Metab 89:4243-4245.
44. Schultz E, Arfai K, Liu X, Sayre J, Gilsanz V. 2004. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246-4253.
45. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. 2003. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 278:50195-50202.
46. Speer MY, Giachelli CM. 2004. Regulation of cardiovascular calcification. Cardiovasc Pathol 13:63-70.
47. Steinberg D. 2002. Atherosclerosis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med 8:1211-1217.
48. Steitz SA, Speer MY, Curinga G, Yang H-Y, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM. 2001. Smooth muscle cell phenotype transition associated with calcification. Upregulation of Cbfa1 and down regulation of muscle lineage markers. Circ Res 89:1147-1154.
49. Stocker R, Keaney JF. 2004. Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381-1478.
50. Trion A, van der Laarse A. 2004. Vascular smooth muscle cells and calcification in ather-sclerosis. Am Heart J 147:808-814.
51. Vattikuti R, Towler DA 2004. Osteogenic regulation of vascular calcification: An early perspective. Am J Physiol Endocrinol Metab 286:E686-E696.
52. Virchow R. 1863/1971. Cellular pathology: As based upon physiological and pathological histology (translated from the original German by F Chance). New York: New York Dover.
53. Wada T, McKee MD, Steitz S, Giachelli CM. 1999. Calcification of vascular smooth muscle cell cultures. Inhibition by osteopontin. Circ Res 84:166-178.
54. Wallin R, Wajih N, Greenwood GT, Sane DC. 2001. Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 21:274-301.
55. Whitfield JF. 2005. Growing bone. Georgetown Texas Landes Biosciewnce, Eureka.com.
56. 2 (Ostabolin). Calcif Tissue Int 58:81-87.
57. 2) to stimulate bone growth in ovariectomized rats. J Bone Miner Res 12:1246-1252.
58. Whitfield JF, Morley P, Willick GE. 2002. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat Endocrinol 1:175-190.
59. Ylitalo R. 2002. Bisphosphonats and atherosclerosis. Gen Pharmacol 35:287-296.
60. Zhu H, Takahashi Y, Xu W, Kawajiri H, Murakami T, Yamamoto M, Iseki S, Iwasaki T, Hattori H, Yoshimoto T. 2003. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J Biol Chem 278:13350-13355.